Plain-English translation of NCT06909604 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a special type of imaging scan called PET imaging can predict how well breast cancer patients will respond to ADC therapy (a targeted cancer treatment). The scan uses a radioactive marker that attaches to HER2 proteins on cancer cells, allowing doctors to see how the cancer is responding to treatment. The goal is to help doctors know early on whether the treatment is working well for each individual patient.
Currently, doctors don't have a reliable way to predict early on which patients will respond well to this medication. By developing this imaging technique, researchers hope to identify responders sooner, so treatment plans can be adjusted quickly if needed—potentially improving outcomes for breast cancer patients.
You likely qualify if…
You likely don't qualify if…
You will undergo a PET imaging scan where a radioactive tracer is injected into your vein, and then you'll lie still inside a scanner for about 30 minutes while it takes pictures of your body. This scan will be done as part of your regular breast cancer treatment monitoring. The study will track how well your cancer responds to treatment and compare that response with the imaging results.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Sponsor
Peking University Cancer Hospital & Institute
Collaborators
The Affiliated Hospital of Qingdao University, North Sichuan Medical College
Enrollment target
~50 participants
Started
January 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaoyi Guo, PhD
Peking University Cancer Hospital & Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.